EU Health technology assessments for medical technologies in 2019

Syndicated report on HTA landscape and all published non-drug HTAs in Europe in 2019, including medical devices and procedures, in-vitro diagnostic tests and e-health solutions

Request a quote

Health technology assessment plays a big role in adoption of medical technologies in Europe. However, due to large number of HTA organizations and complexity of HTA schemes, the activity and their impact on reimbursement and funding decisions is not well understood. 

We developed an overview of all non-drug HTAs in 2019 to help industry to understand HTA landscape, the role of individual HTA organizations, their activity in relation to number of HTA reports and types of technologies covered. 

Report is delivered in the Acrobat PDF version.

This report complements the series of MTRC analytical reports in the field of reimbursement for medical technologies, including reports on innovation funding schemes in 2021 and funding frameworks and decisions for medical technologies.

Key features of the report

12 EU countries

HTA organizations from 12 EU countries (Austria, Belgium, Denmark, England, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland) + EUnetHTA

51 HTA organizations

All existing organizations are reviewed including EUnetHTA, national and regional HTA bodies

Medical devices, IVD tests and e-health solutions

Data about all non-drug assessments are included into the report

Overview of individual organizations

Brief overview of the role of each organization is provided

Summary statistics

Number of reports per country, per HTA body (program), per type of technology (e.g. neurostimulator, cardiovascular) is included

List of all published reports (n=256)

All HTA reports per country/organization are listed in the table format including organization, title, type of technology and web-link. Optionally, access the full list in MS Excel

Obtain sample pages

Click to the link below to obtain sample pages, including the whole section on HTA landscape and 2019 reports for medical technologies in Norway

Get sample pages

Specifics of the report

Austria: Assessments from the Ludwig Boltzmann Institute – Health Technology Assessment (LBI-HTA)

Belgium: Assessments from Belgian Health Care Knowledge Center (KCE)

Denmark: Activity of four Danish HTA organizations

England: All Med Tech, procedure and IVD programs at NICE and HTA Programme at National Institute for Health Research

Finland: Assessments from the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)

France: Limited only to National Authority for Health (HAS). Three types of assessments are included: stand-alone HTA reports, assessments of CNEDiMTS in relation to LPPR registration for medical aids, implants and invasive devices; assessments in relation to registration of reimbursement codes for IVD tests (NABM)

Germany: Assessments from the Quality and Efficiency in Health Care (IQWiG)

Italy: Activity of 13 national and regional HTA organizations

Netherlands: Assessments in relation to coverage with Basic Health Insurance by the National Healthcare Institute (Zorginstitute Netherland)

Norway: Stand-alone assessments from Norwegian Institute of Public Health (NIPH); assessments at national and hospital level in connection with "New Methods" framework. Evidence summaries from NIPH for shared decision-making with patients were not included. Brief evidence notes, prepared by NIPH on request from Ordering Forum of "New Methods" framework were not included as well.

Spain: Activity of eight national and regional HTA organizations

Sweden: Activity of eight national and regional HTA organizations. At TLV, only health economic evaluations of medical devices were considered. Reviews of medical aids were not included

Switzerland. Assessments from the Swiss Medical Board

Request a quote

Click the button below to request a quote for the report


50% Complete

Two Step

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.